scholarly journals Association Between Urinary Type IV Collagen Level and Deterioration of Renal Function in Type 2 Diabetic Patients Without Overt Proteinuria

Diabetes Care ◽  
2010 ◽  
Vol 33 (8) ◽  
pp. 1805-1810 ◽  
Author(s):  
S.-i. Araki ◽  
M. Haneda ◽  
D. Koya ◽  
K. Isshiki ◽  
S. Kume ◽  
...  
Keyword(s):  
Renal Function ◽  
Type Iv Collagen ◽  
Diabetic Patients ◽  
Type 2 Diabetic Patients ◽  
Type Iv ◽  
Collagen Level ◽  
Overt Proteinuria ◽  
Type 2 Diabetic

Urinary type IV collagen excretion predicts subsequent declining renal function in type 2 diabetic patients with proteinuria

2010 ◽  
Vol 89 (2) ◽  
pp. e33-e35 ◽  
Author(s):  
Pisut Katavetin ◽  
Paravee Katavetin ◽  
Paweena Susantitaphong ◽  
Natavudh Townamchai ◽  
Khajohn Tiranathanagul ◽  
...  
Keyword(s):  
Renal Function ◽  
Type Iv Collagen ◽  
Diabetic Patients ◽  
Type 2 Diabetic Patients ◽  
Type Iv ◽  
Type 2 Diabetic

scholarly journals The effect of HIV infection on glycaemia and renal function in type 2 diabetic patients

PLoS ONE ◽  
2018 ◽  
Vol 13 (6) ◽  
pp. e0199946 ◽  
Author(s):  
Siyabonga P. Khoza ◽  
Nigel J. Crowther ◽  
Sindeep Bhana
Keyword(s):  
Renal Function ◽  
Hiv Infection ◽  
Diabetic Patients ◽  
Type 2 Diabetic Patients ◽  
Type 2 Diabetic

scholarly journals Effects of sodium-glucose co-transporter 2 (SGLT2) inhibition on renal function and albuminuria in patients with type 2 diabetes: a systematic review and meta-analysis

PeerJ ◽  
2017 ◽  
Vol 5 ◽  
pp. e3405 ◽  
Author(s):  
Lubin Xu ◽  
Yang Li ◽  
Jiaxin Lang ◽  
Peng Xia ◽  
Xinyu Zhao ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Renal Function ◽  
Diabetic Patients ◽  
Controlled Trials ◽  
Cochrane Central Register ◽  
Type 2 Diabetic Patients ◽  
Sglt2 Inhibition ◽  
Type 2 Diabetic

Aim To evaluate the effects of sodium-glucose co-transporter 2 (SGLT2) inhibition on renal function and albuminuria in patients with type 2 diabetes. Methods We conducted systematic searches of PubMed, Embase and Cochrane Central Register of Controlled Trials up to June 2016 and included randomized controlled trials of SGLT2 inhibitors in adult type 2 diabetic patients reporting estimated glomerular filtration rate (eGFR) and/or urine albumin/creatinine ratio (ACR) changes. Data were synthesized using the random-effects model. Results Forty-seven studies with 22,843 participants were included. SGLT2 inhibition was not associated with a significant change in eGFR in general (weighted mean difference (WMD), −0.33 ml/min per 1.73 m2, 95% CI [−0.90 to 0.23]) or in patients with chronic kidney disease (CKD) (WMD −0.78 ml/min per 1.73 m2, 95% CI [−2.52 to 0.97]). SGLT2 inhibition was associated with eGFR reduction in short-term trials (WMD −0.98 ml/min per 1.73 m2, 95% CI [−1.42 to −0.54]), and with eGFR preservation in long-term trials (WMD 2.01 ml/min per 1.73 m2, 95% CI [0.86 to 3.16]). Urine ACR reduction after SGLT2 inhibition was not statistically significant in type 2 diabetic patients in general (WMD −7.24 mg/g, 95% CI [−15.54 to 1.06]), but was significant in patients with CKD (WMD −107.35 mg/g, 95% CI [−192.53 to −22.18]). Conclusions SGLT2 inhibition was not associated with significant changes in eGFR in patients with type 2 diabetes, likely resulting from a mixture of an initial reduction of eGFR and long-term renal function preservation. SGLT2 inhibition was associated with statistically significant albuminuria reduction in type 2 diabetic patients with CKD.

scholarly journals Cystatin C and collagen type IV in diagnostics of chronic kidney disease in type 2 diabetic patients

2015 ◽  
Vol 18 (1) ◽  
pp. 87-93 ◽  
Author(s):  
Vadim Valer'evich Klimontov ◽  
Nadezhda Valentinovna Eremenko ◽  
Natalya Evgen'evna Myakina ◽  
Olga Nikolaevna Fazullina
Keyword(s):  
Cystatin C ◽  
Collagen Type ◽  
Collagen Type Iv ◽  
Diabetic Patients ◽  
Serum Cystatin C ◽  
Type 2 Diabetic Patients ◽  
Serum Cystatin ◽  
Type Iv ◽  
Type 2 Diabetic

Aim. To compare kidney disease markers: glomerular filtration rate (GFR), calculated upon creatinine and cystatin C, urinary cystatin C, collagen type IV and albumin in type 2 diabetic patients with normal and moderately reduced renal function. Materials and methods. 56 patients, aged 43?70 years, and 16 healthy controls, aged 40-72 years, were included in the study. GFR was calculated by equations based on creatinine (CKD-EPIcreat), cystatin C (CKD-EPIcys) or both markers (CKD-EPIcreat-cys). Serum and urinary cystatin C was measured by immunoturbidimetric method, urinary albumin, albumin excretion rate (AER) and collagen type IV excretion was determined by ELISA. The body composition was investigated in 24 patients by dual-energy X-ray absorptiometry. Results. In diabetic patients serum cystatin C level correlated positively with age (r=0.37), GFR calculated by CKD-EPIcreat (r=-0.43) and fat mass percentage (r=0.55). There was a positive correlation between GFR calculated by the CKD-EPIcys and GFR by CKD-EPIcreat (r=0.48). In multiple regression analysis the percentage of body fat influenced the GFR calculated by CKD-EPIcys or CKD-EPIcreat-cys. No correlation between urinary cystatin C and serum cystatin C level, GFR and AER was found. Collagen type IV excretion was increased in patients with decreased GFR, compared to those with normal GFR (p=0.002). Urinary collagen type IV correlated with both GFR and AER (r=-0.28 and r=0.47). Conclusion. The measurement of serum cystatin C with calculation of GFR by CKD-EPIcys and CKD-EPIcreat-cys, in addition to the CKD-EPIcreat, increases the accuracy of CKD diagnostics in type 2 diabetic patients. However, obesity and particularly body fat mass affect the results of estimation of GFR based on cystatin C. The increase in urinary collagen type IV, but not in cystatin C excretion, is related to GFR decline and AER elevation in these patients.

Sign in / Sign up

Export Citation Format

Share Document